Lixte Biotechnology Holdings, Inc., a development stage company, develops new treatments for human cancers. The scope of potential applications of the company’s products has expanded to other common non-malignant diseases, including vascular diseases (heart attacks and stroke, diabetes, and genetic diseases, such as Gaucher’s disease) in which errors in normal cellular processing lead to loss of functions important to normal cell function. The company’s drug discovery process is based on discerning clues to potential new targets for disease treatments reported in the increasingly large body of literature identifying the molecular variants, which characterize human cancers and other non-cancer disorders. The company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The company develops two classes of drugs for the treatment of cancer, protein phosphatase inhibitors (PTase-i), designated by it as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by it as the LB-200 series of compounds. Compounds of both types also have potential use in the prevention and treatment of neurodegenerative diseases. The LB-100 series consists of novel structures, which have the potential to be first in their class, and may be useful in the treatment of not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which have the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases. Intellectual Property The company’s products would derive directly from its intellectual property, including the property covered by its patents. These patents cover sole rights to the composition and synthesis of the LB-100 and LB-200 series of drugs. Joint patent applications with the NIH have been filed for the treatment of glioblastoma multiforme, medulloblastoma, and neuroblastoma. The company has also filed claims for the use of certain homologs of both series of drugs for the potential treatment of neurodegenerative diseases, such as Alzheimer’s Disease and Parkinson’s Disease, Amyotrophic Lateral Sclerosis, stroke, and traumatic brain injury and of homologs of the LB-200 series for treatment of serious systemic fungal infections and for the treatment of common fungal infections of the skin and nails. Government Regulation The company’s business is subject to the regulations of the United States Food and Drug Administration as it conducts clinical trials. History Lixte Biotechnology Holdings, Inc. was founded in 2005.
lixte biotechnology holdings
248 Route 25A, No. 2
East Setauket, NY 11733
|No competitor information is available for LIXT.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact LIXTE BIOTECHNOLOGY HOLDINGS, please visit www.lixte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.